Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Income: 2014-2025

Historic Net Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$35.1 million.

  • Viridian Therapeutics, Inc.\DE's Net Income rose 54.18% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 17.75%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Net Income of -$35.1 million as of Q3 2025, which was up 65.20% from -$100.7 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Net Income ranged from a high of -$14.0 million in Q3 2021 and a low of -$100.7 million during Q2 2025.
  • Moreover, its 3-year median value for Net Income was -$66.9 million (2023), whereas its average is -$66.4 million.
  • Over the last 5 years, Viridian Therapeutics, Inc.\DE's Net Income had its largest YoY gain of 68.11% in 2021, and its largest YoY loss of 177.41% in 2021.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Net Income stood at -$28.9 million in 2021, then slumped by 58.17% to -$45.8 million in 2022, then crashed by 46.03% to -$66.9 million in 2023, then declined by 19.33% to -$79.8 million in 2024, then skyrocketed by 54.18% to -$35.1 million in 2025.
  • Its Net Income was -$35.1 million in Q3 2025, compared to -$100.7 million in Q2 2025 and -$86.9 million in Q1 2025.